HC Wainwright Issues Pessimistic Forecast for JBIO Earnings

Jade Biosciences, Inc. (NASDAQ:JBIO) – Analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for Jade Biosciences in a research note issued on Tuesday, May 12th. HC Wainwright analyst A. He now forecasts that the company will earn ($0.62) per share for the quarter, down from their previous forecast of ($0.50). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Jade Biosciences’ current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Jade Biosciences’ Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($2.45) EPS, FY2027 earnings at ($2.58) EPS, FY2028 earnings at ($2.63) EPS, FY2029 earnings at ($2.66) EPS and FY2030 earnings at ($2.04) EPS.

Jade Biosciences (NASDAQ:JBIO) last released its earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.05).

Several other research firms have also issued reports on JBIO. Wall Street Zen lowered Jade Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Zacks Research upgraded Jade Biosciences from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Lifesci Capital upgraded Jade Biosciences to a “strong-buy” rating in a research note on Friday, March 6th. BTIG Research upped their price objective on Jade Biosciences from $28.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Finally, William Blair upgraded Jade Biosciences to a “strong-buy” rating in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.33.

Jade Biosciences Stock Down 0.6%

JBIO stock opened at $25.07 on Thursday. The firm has a market cap of $1.24 billion, a PE ratio of -12.41 and a beta of 1.52. The business has a 50 day moving average of $18.49 and a 200-day moving average of $15.36. Jade Biosciences has a 12-month low of $6.57 and a 12-month high of $28.00.

Institutional Investors Weigh In On Jade Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc purchased a new stake in shares of Jade Biosciences in the second quarter worth $29,000. Russell Investments Group Ltd. purchased a new stake in shares of Jade Biosciences in the second quarter worth $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Jade Biosciences in the second quarter worth $32,000. California State Teachers Retirement System raised its position in shares of Jade Biosciences by 40.3% in the fourth quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock worth $44,000 after buying an additional 819 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Jade Biosciences by 4,180.3% in the third quarter. New York State Common Retirement Fund now owns 5,222 shares of the company’s stock worth $45,000 after buying an additional 5,100 shares in the last quarter.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.